Integrated CDK Inhibitor Systems for Personalized Cancer Therapy
Legal Citation
Summary of the Inventive Concept
A novel approach combining CDK inhibitor compounds with cutting-edge technologies such as AI, IoT, blockchain, and advanced materials to create a powerful system for personalized cancer treatment and monitoring.
Background and Problem Solved
The original patent disclosed CDK inhibitor compounds, which, although effective, have limitations in terms of treatment outcomes and patient monitoring. The new inventive concept addresses these limitations by integrating the CDK inhibitor compounds with distinct technologies to create a more comprehensive and effective system.
Detailed Description of the Inventive Concept
The new system comprises an APPAMP compound, an artificial intelligence module for optimizing treatment regimens, a blockchain-based platform for secure sharing of patient health records and genomic data, an IoT-enabled sensor for real-time monitoring of treatment efficacy, and a nanoparticle-based delivery system for targeted cancer treatment. The AI module utilizes patient-specific genomic data to predict treatment outcomes, while the blockchain platform ensures secure sharing of data between healthcare providers. The IoT sensor provides real-time monitoring of treatment efficacy, and the nanoparticle-based delivery system targets specific cancer cells.
Novelty and Inventive Step
The integration of CDK inhibitor compounds with AI, IoT, blockchain, and advanced materials is new and non-obvious, as it combines distinct technologies to create a more powerful and effective system for personalized cancer treatment and monitoring.
Alternative Embodiments and Variations
Alternative embodiments include integrating the CDK inhibitor compounds with other AI algorithms, using different blockchain platforms, or incorporating additional IoT sensors. Variations may include using different nanoparticle materials or targeting different types of cancer cells.
Potential Commercial Applications and Market
The integrated CDK inhibitor system has significant commercial potential in the personalized cancer therapy market, with potential applications in hospitals, research institutions, and pharmaceutical companies. The system's ability to provide personalized treatment regimens, secure data sharing, and real-time monitoring of treatment efficacy makes it an attractive solution for healthcare providers and patients.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, oncology, and computational biology, with expertise in CDK inhibitor design, cancer treatment technologies, and computational drug discovery methods
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in pharmaceutical chemistry or molecular biology, experienced in drug design, computational modeling, and understanding of targeted cancer therapies, with knowledge of interdisciplinary technologies including AI, blockchain, and nanotechnology
Obviousness Rationale
A PHOSITA would recognize that integrating CDK inhibitor compounds with advanced computational and monitoring technologies represents a predictable extension of existing pharmaceutical research methodologies. The combination of targeted drug delivery, personalized treatment optimization, and data management technologies follows established trends in precision medicine. The technical variations disclosed represent logical combinations of known techniques in pharmaceutical research and digital health technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,552 |
|---|---|
| Title | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors |
| Assignee(s) | CARRICK THERAPEUTICS LIMITED |